James N. Topper
Millennium Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James N. Topper.
Journal of Biological Chemistry | 2003
Ruey-Bing Yang; Chi Kin Domingos Ng; Scott M. Wasserman; Laszlo G. Komuves; Mary Gerritsen; James N. Topper
We have previously utilized a combination of high throughput sequencing and genome-wide microarray profiling analyses to identify novel cell-surface proteins expressed in human umbilical vein endothelial cells. One gene identified by this approach encodes a type I transmembrane receptor that shares sequence homology with the intracellular domain of members of the interleukin-17 (IL-17) receptor family. Real-time quantitative PCR and Northern analyses revealed that this gene is highly expressed in human umbilical vein endothelial cells and in several highly vascularized tissues such as kidney, colon, skeletal muscle, heart, and small intestine. In addition, we also found that it is also highly expressed in the ductal epithelial cells of human salivary glands, seminal vesicles, and the collecting tubules of the kidney by in situ hybridization. This putative receptor, which we have termed human SEF (hSEF), is also expressed in a variety of breast cancer tissues. In co-immunoprecipitation assays, this receptor is capable of forming homomeric complexes and can interact with fibroblast growth factor (FGF) receptor 1. Overexpression of this receptor inhibits FGF induction of an FGF-responsive reporter gene in human 293T cells. This appears to occur as a result of specific inhibition of p42/p44 ERK in the absence of upstream MEK inhibition. This inhibitory effect is dependent upon a functional intracellular domain since deletion mutants missing the IL-17 receptor-like domain lack this inhibitory effect. These findings are consistent with the recent discovery of the zebrafish homologue, Sef (similar expression to fgf genes), which specifically antagonizes FGF signaling when ectopically expressed in zebrafish or Xenopus laevis embryos. Based on sequence and functional similarities, this novel IL-17 receptor homologue represents a potential human SEF and is likely to play critical roles in endothelial or epithelial functions such as proliferation, migration, and angiogenesis.
Arteriosclerosis, Thrombosis, and Vascular Biology | 2002
Takeshi Nakahashi; Katsuyuki Hoshina; Philip S. Tsao; Eiketsu Sho; Mien Sho; John K. Karwowski; Cory Yeh; Ruey-Bing Yang; James N. Topper; Ronald L. Dalman
Objective—Reactive oxygen species may act as proinflammatory mediators in abdominal aortic aneurysm (AAA) disease. Flow loading increases antioxidative enzyme expression and limits reactive oxygen species production in vascular smooth muscle cells in vitro, limits experimental AAA enlargement in rodent models, and is indirectly associated with reduced clinical AAA risk. We attempted to determine the mechanism or mechanisms by which flow loading limits AAA enlargement. Methods and Results—Rodent AAAs were flow loaded via femoral arteriovenous fistula creation. Aortic wall shear stress and relative wall strain were significantly higher in flow-loaded rodents. Flow loading reduced AAA diameter by 26% despite evidence of flow-mediated aortic enlargement proximal to the aneurysmal segment. Messenger RNA from AAA tissue was harvested for cDNA labeling and hybridization to a 384-clone DNA microarray. Twenty-nine genes were differentially expressed (relative intensity/relative intensity of control ratio >1.5 and <0.67) in flow-loaded compared with normal flow AAA tissue, including heme oxygenase 1 (HO-1). Increased HO-1 expression was confirmed via reverse transcriptase–polymerase chain reaction. Immunohistochemistry localized HO-1 expression to infiltrative macrophages. &agr;-Tocopherol was found to be as effective as flow loading in limiting AAA enlargement. Flow loading and &agr;-tocopherol therapy reduced AAA reactive oxygen species production. Conclusions—Flow loading may attenuate AAA enlargement via wall shear or strain-related reductions in oxidative stress.
Vascular Medicine | 2004
Scott M. Wasserman; James N. Topper
Biomechanical forces generated by blood flow play an important role in the pathogenesis of vascular disease. For example, regions exposed to non-uniform shear stresses develop early atherosclerotic lesions while areas exposed to uniform shear stresses are protected. A variety of in vitro flow apparatuses have been created to apply well-characterized flow patterns to endothelial cells in an effort to dissect the cellular and molecular pathways involved in these distinct processes. Recent advances in biotechnology have permitted large-scale transcriptional profiling techniques to replace candidate gene screens and have allowed the genome-wide examination of biomechanical force-induced endothelial gene expression profiles. This review provides an overview of biomechanical force-induced modulation of endothelial phenotype. It examines the effect of sustained laminar shear stress (LSS), a type of uniform shear stress, on in vitro endothelial gene expression by synthesizing data from the early candidate gene and differential display polymerase chain reaction (PCR) approaches to the numerous, recent, high throughput functional genomic analyses. These studies demonstrate that prolonged LSS regulates the expression of only a small percentage (1-5%) of endothelial genes, and this transcriptional profile produces an endothelial phenotype that is quiescent, being protected from apoptosis, inflammation and oxidative stress. These observations provide a possible molecular mechanism for the strong correlation between patterns of blood flow and the occurrence of vascular pathologies, such as atherosclerosis, in vivo.
Physiological Genomics | 2002
Scott M. Wasserman; Fuad Mehraban; Laszlo G. Komuves; Ruey-Bing Yang; James E. Tomlinson; Ying Zhang; Frank Spriggs; James N. Topper
Journal of Biological Chemistry | 2002
Ruey-Bing Yang; Chi Kin Domingos Ng; Scott M. Wasserman; Steven D. Colman; Suresh Shenoy; Fuad Mehraban; Laszlo G. Komuves; James E. Tomlinson; James N. Topper
Blood | 2008
Liming Milbauer; Peng Wei; Judy Enenstein; Aixiang Jiang; Cheryl A. Hillery; J. Paul Scott; Stephen C. Nelson; Vidya Bodempudi; James N. Topper; Ruey-Bing Yang; Betsy Hirsch; Wei Pan; Robert P. Hebbel
Archive | 2003
Ruey-Bing Yang; Chi Kin Domingos Ng; James E. Tomlinson; Laszlo G. Komuves; James N. Topper; Keith E. Robison
Current Atherosclerosis Reports | 2003
James E. Tomlinson; James N. Topper
Blood | 2007
Robert P. Hebbel; Peng Wei; Aixiang Jiang; Cheryl A. Hillery; J. Paul Scott; Stephen C. Nelson; Judy Enenstein; Liming Milbauer; Vidya Bodempudi; Wei Pan; Betsy Hirsch; James N. Topper; Ruey-Bing Yang
Blood | 2008
Mary E. Fabry; Liming Milbauer; Peng Wei; Judy Enenstein; Aixiang Jiang; Cheryl A. Hillery; J. Paul Scott; Stephen C. Nelson; Vidya Bodempudi; James N. Topper; Ruey-Bing Yang; Betsy Hirsch; Wei Pan; Robert P. Hebbel